This guide reviews interventions for people living with substance use and mental disorders who are at risk for or living with HIV. Selected interventions are in alignment with goals of the federal “Ending the HIV Epidemic: A Plan for America” (EHE) initiative.

This guide explores barriers to accessing substance use disorder and mental health treatment services in rural communities, and the benefits of telehealth for these communities. It assists practitioners with implementing telehealth technologies as a means to increase access to services.

The report highlights the need for HIV treatment providers to address behavioral health concerns with HIV. The report urges providers to start with screening for mental health and substance use disorders, and offers strategies for providers to implement screening practices.

This hepatitis C education training guide provides counselors and other clinical staff with a scripted plan to use with patients and their families in behavioral health treatment.

This quick guide helps clinicians address viral hepatitis when working with people living with substance use disorders. It covers hepatitis prevention, screening, treatment, and service coordination, and guides administrators on how to add or improve hepatitis services.

This quick guide helps administrators of substance use disorder treatment facilities implement programs and services that address the needs of women living with substance use disorders. It addresses patterns of use and the drug screening and treatment needs of women.

This report presents the key principles and core expectations of the State Epidemiological Outcomes Workgroups. The workgroups are designed to use data to inform and enhance state and community decisions regarding substance use and mental illness prevention programs.

This manual guides counselors in the use of medications to help clients achieve abstinence from alcohol. It describes how the medications work and whom may benefit. It also presents the side effects of three FDA-approved medications: acamprosate, disulfiram, and naltrexone.